Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report

doi:10.12998/wjcc.v10.i21.7502

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3490)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

187

WORD

HTML

1796

Figures (1-3)

303

Tables (1-1)

372

Sum=2714

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

198

Download

578

Sum=776

Jul 26, 2022 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Jul 26, 2022; 10(21): 7502-7508
Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7502

Table 1 Pertinent literature

Ref.	Date	Sex	Age (yr)	Diagnosis	Response	Follow-up time (mo)
Chong et al[18]	2017	M	35	DLBCL	PR	12
Wang et al[19]	2019	F	70	FL	CR	10
Zhang et al[20]	2021	F	37	DLBCL	PR	17
Our case	2022	M	41	DLBCL	PR	12

M: Male; F: Female; FL: Follicular lymphoma; DLBCL: Diffuse large B cell lymphoma; PR: Partial complete remission; CR: Complete complete remission.

Citation: Zhang CJ, Zhang JY, Li LJ, Xu NW. Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report. World J Clin Cases 2022; 10(21): 7502-7508
URL: https://www.wjgnet.com/2307-8960/full/v10/i21/7502.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i21.7502